<DOC>
	<DOCNO>NCT01874639</DOCNO>
	<brief_summary>Blood loss hepatic surgery main factor postoperative morbidity . The use effective possible tool hemostasis allow bleed decrease liver transection thus could reduce postoperative morbidity . In past decade , improvement technique transection hepatic parenchyma one important factor ensure hepatectomy safety . But clinical performance technological innovation ( ultrasound dissectors , monopolar radiofrequency probe dissection device use pressurized water ) remain still unclear . The medical device hemostasis Aquamantys® ( Salient company , Innopath ) use technology `` transcollation '' combine source radiofrequency associate conductive liquid ( NaCl 0.9 % solution ) . The system consist specific generator ( Aquamantys Pump Generator® ) single-use probe ( Aquamantys 2.3 BipolarSealer® ) . The energy radiofrequency deliver two bipolar electrode . The innovative aspect device consist maintain tissue temperature 100°C , use conductive liquid act process cool avoids dry tissue , smoke , risk electric arc overheat meet conventional electrosurgery . This device allow coagulation blood vessel also bile duct . The Aquamantys® system could decrease postoperative morbidity mortality due decrease blood loss biliary leak . These clinical benefit could translate improvement direct indirect cost associate surgery . However Aquamantys® technology scientifically validate context hepatic surgery , technology expensive due purchase single-use bipolar probe ( Aquamantys 2.3 BipolarSealer® ) investment generator ( Aquamantys Pump Generator® ) . Consequently , essential realize study measure clinical medical economic impact transcollation technology ( Aquamantys® device ) hepatic surgery .</brief_summary>
	<brief_title>Use Transcollation Device Decrease Blood Loss During Hepatic Resections : Randomized Cohort Study ( HEPACOLL )</brief_title>
	<detailed_description>After validation inclusion exclusion criterion , patient include clinical trial randomize two arm study : - Control group : hepatectomy conventional hemostasis use standard bipolar coagulation - Test group : hepatectomy Aquamantys®</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<criteria>Patients undergo elective surgery liver resection malignant benign disease Hepatic resection two segment No coagulation disorder No portal hypertension ( platelet ≥ 100 G/L , absence splenomegaly , absence portal hypertension varix ) Obtaining patient 's write consent Age &lt; 18 year &gt; 80 year ASA score &gt; 3 Cirrhosis , liver fibrosis &gt; F2 , steatosis &gt; 60 % , sinusoidal obstruction syndrome Cognitive trouble major disability make impossible understand study sign inform consent ( e.g . dementia , psychiatric disorder like psychosis , speech disorder ... ) Liver kidney failure Pregnancy lactate woman Legal incapacity Patients already enrol clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Hepatectomy</keyword>
	<keyword>blood loss</keyword>
	<keyword>hemostasis</keyword>
	<keyword>coagulation</keyword>
	<keyword>Liver surgery ( benign malign )</keyword>
	<keyword>Resection 2 segment</keyword>
</DOC>